

# Discovery of a novel lead compound for chronic pain treatments using a TRPV1 binding peptides design and manufacture platform

Gachon University



NEUROSCIENCE	Lead
Product Type	Peptide
Indication	Chronic pain
Target	TRPV1 channel
MoA(Mechanism of Action)	Direct inhibition of TRPV1 channel that causes abnormal neural signal and hyperexcitability in chronic pain
Competitiveness	<ul style="list-style-type: none"> <li>• Effectiveness: in vitro (IC<sub>50</sub> &lt; 1 nM) / in vivo analgesic effect lasts 24 h</li> <li>• Site specificity: extracellular motif of TRPV1 channel targeting</li> <li>• Lead compound library: currently screening 50 types derived from lead compounds</li> <li>• Stabilization strategies: N/C-terminal cyclization or microsphere encapsulation</li> </ul>
Development Stage	Lead
Route of Administration	Subcutaneous Injection